Rossi Isabelle A, Zuber Patrick L F, Dumolard Laure, Walker Damian G, Watt James
Institute of Social and Preventive Medicine, University of Lausanne, rue du Bugnon 17, 1005 Lausanne, Switzerland.
Vaccine. 2007 Oct 10;25(41):7075-80. doi: 10.1016/j.vaccine.2007.07.058. Epub 2007 Aug 15.
Despite the demonstration of effectiveness and public health impact of Hib conjugate vaccines, the majority of infants from poorest countries do not yet have access to this safe and effective preventive intervention. This paper provides a descriptive analysis of the main characteristics of countries that have included Hib vaccine in their national immunization programmes before 2006. It highlights the importance of regularly analyzing the process of decision-making involved in implementation of public health interventions, in order to learn from cumulative experience and expedite the introduction of future interventions.
尽管已证明b型流感嗜血杆菌结合疫苗具有有效性和公共卫生影响，但大多数最贫穷国家的婴儿仍无法获得这种安全有效的预防性干预措施。本文对在2006年之前将b型流感嗜血杆菌疫苗纳入其国家免疫规划的国家的主要特征进行了描述性分析。它强调了定期分析公共卫生干预措施实施过程中决策过程的重要性，以便从累积经验中学习并加快未来干预措施的引入。
